# Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

> **NCT04531397** · PHASE4 · WITHDRAWN · sponsor: **Children's Hospital of Fudan University**

## Conditions studied

- Proteinuria
- Chronic Kidney Diseases

## Interventions

- **DRUG:** ACEI treatment
- **DRUG:** Dapagliflozin+ACEI treatment

## Key facts

- **NCT ID:** NCT04531397
- **Lead sponsor:** Children's Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531397, "Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04531397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*